D-Cycloserine for Treatment Nonresponders With Obsessive-Compulsive Disorder: A Case Report

Cognitive and Behavioral Practice

Volumn 19, Issue 2, 2012, Pages 338-345

  Norberg, Melissa M ^a   Gilliam, Christina M ^b   Villavicencio, Anna ^b   Pearlson, Godfrey D ^b   Tolin, David F ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Behavior therapy; D Cycloserine; Exposure and response prevention; Obsessive compulsive disorder; Treatment nonresponder

Indexed keywords

AMFEBUTAMONE; CLOMIPRAMINE; CYCLOSERINE; DULOXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; CASE REPORT; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; EXPOSURE AND RESPONSE PREVENTION; FEMALE; FOLLOW UP; GENERALIZED ANXIETY DISORDER; HUMAN; MAJOR DEPRESSION; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOSOCIAL CARE; RELAPSE; TIME SERIES ANALYSIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 84858446664     PISSN: 10777229     EISSN: 1878187X     Source Type: Journal    
DOI: 10.1016/j.cbpra.2011.05.002     Document Type: Article

References (41)

1. Baker J.D., Azorlosa J.L. The NMDA antagonist MK-801 blocks the extinction of Pavlovian fear conditioning. Behavioral Neuroscience 1996, 110:618-620.
2. Brown T.A., Chorpita B.F., Korotitsch W., Barlow D.H. Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples. Behaviour Research and Therapy 1997, 35:79-89.
3. Buchanan A.W., Meng K.S., Marks I.M. What predicts improvement and compliance during the behavioral treatment of obsessive compulsive disorder?. Anxiety 1996, 2:22-27.
4. Chasson G.S., Buhlmann U., Tolin D.F., Rao S.R., Reese H.E., Rowley T., Wilhelm S. The need for speed: Evaluating slopes of OCD recovery in behavior therapy enhanced with D-cycloserine. Behaviour Research and Therapy 2010, 48:675-679.
5. Cox J., Westbrook R.F. The NMDA receptor antagonist MK-801 blocks acquisition and extinction of conditioned hypoalgesic responses in the rat. Quarterly Journal of Experimental Psychology 1994, 47:187-210.
6. Davis M. Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: clinical implications for exposure therapy. European Journal of Neuroscience 2002, 16:395-398.
7. Eisen J.L., Phillips K.A., Baer L., Beer D.A., Atala K.D., Rasmussen S.A. The Brown Assessment of Beliefs Scale: Reliability and validity. American Journal of Psychiatry 1998, 155:102-108.
8. Fanselow M.S., LeDoux J.E. Why we think plasticity underlying Pavlovian fear conditioning occurs in the basolateral amygdala. Neuron 1999, 23:229-232.
9. Ferrao Y.A., Shavitt R.G., Bedin N.R., de Mathis M.E., Carlos Lopes A., Fontenelle L.F., Miguel E.C. Clinical features associated to refractory obsessive-compulsive disorder. Journal of Affective Disorders 2006, 94:199-209.
10. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID I/P, version 2.0) 1995, Biometrics Research Department, New York.
11. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Personality Disorders, (SCID-II) 1997, American Psychiatric Press, Inc., Washington, D.C.
12. Fisher P.L., Wells A. How effective are cognitive and behavioral treatments for obsessive-compulsive disorder? A clinical significance analysis. Behaviour Research and Therapy 2005, 43:1543-1558.
13. Foa E.B., Kozak M.J. Mastery of obsessive-compulsive disorder: A cognitive-behavioral approach (therapist guide) 1997, Oxford University Press, New York.
14. Foa E.B., Liebowitz M.R., Kozak M.J., Davies S., Campeas R., Franklin M.E., Tu X. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. American Journal of Psychiatry 2005, 162:151-161.
15. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Delgado P., Heninger G.R., Charney D.S. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Archives of General Psychiatry 1989, 46:1012-1016.
16. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., Charney D.S. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Archives of General Psychiatry 1989, 46:1006-1011.
17. Goosens K.A., Maren S. Long-term potentiation as a substrate for memory: evidence from studies of amygdaloid plasticity and Pavlovian fear conditioning. Hippocampus 2002, 12:592-599.
18. Guastella A.J., Dadds M.R., Lovibond P.F., Mitchell P., Richardson R. A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. Journal of Psychiatric Research 2007, 41:466-471.
19. Guastella A.J., Lovibond P.F., Dadds M.R., Mitchell P., Richardson R. A randomized controlled trial of the effect of D-cycloserine on extinction and fear conditioning in humans. Behavior Research and Therapy 2007, 45:663-672.
20. Kazdin A.E. Methodological issues and strategies in clinical research 1998, American Psychological Association, Washington, DC. 2nd ed.
21. Koran L.M., Hanna G.L., Hollander E., Nestadt G., Simpson H.B. Practice guideline for the treatment of patients with obsessive-compulsive disorder. American Journal of Psychiatry 2007, 164:5-53.
22. Kushner M.G., Kim S.W., Donahue C., Thuras P., Adson D., Kotlyar M., Foa E.B. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biological Psychiatry 2007, 62:835-838.
23. Lovibond P.F., Lovibond S.H. The structure of negative emotional states: Comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behavior Research and Therapy 1995, 33:335-343.
24. Lovibond S.H., Lovibond P.F. Manual for the Depression Anxiety Stress Scales 1995, The Psychology Foundation of Australia, Sydney.
25. Norberg M.M., Calamari J.E., Cohen R.J., Riemann B.C. Quality of life in obsessive-compulsive disorder: an evaluation of impairment and a preliminary analysis of the ameliorating effects of treatment. Depression and Anxiety 2008, 25:248-259.
26. Norberg M.M., Krystal J.H., Tolin D.F. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biological Psychiatry 2008, 63:1118-1126.
27. Pallanti S., Quercioli L. Treatment-refractory obsessive-compulsive disorder: Methodological issues, operational definitions and therapuetic lines. Progress in Neuro-psychopharmacology and Biological Psychiatry 2006, 30:400-412.
28. Rogan M.T., Staubli U.V., LeDoux J.E. Fear conditioning induces associative long-term potentiation in the amygdala. Nature 1997, 390:604-607.
29. Royer S., Pare D. Bidirectional synaptic plasticity in intercalated amygdala neurons and the extinction of conditioned fear responses. Neuroscience 2002, 115:455-462.
30. Simpson H.B., Liebowitz M.R., Foa E.B., Kozak M.J., Schmidt A.B., Rowan V., Franklin M.E. Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depression and Anxiety 2004, 19:225-233.
31. Steketee G., Frost R., Bogart K. The Yale-Brown Obsessive Compulsive Scale: Interview versus self-report. Behaviour Ressearch and Therapy 1996, 34:675-684.
32. Storch E.A., Merlo L.J., Bengtson M., Murphy T.K., Lewis M.H., Yang M.C., Goodman W.K. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. International Clinical Psychopharmacology 2007, 22:230-237.
33. Storch E.A., Murphy T.K., Goodman W.K., Geffken G.R., Lewin A.B., Henin A., Geller D.A. A preliminary study of D-Cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biological Psychiatry 2010, 68:1073-1076.
34. Tolin, D. F. (2012). Combining pharmacotherapy and psychological treatments for OCD. In G. Steketee (Ed.), Oxford handbook of obsessive compulsive and spectrum disorders (pp. 365-375). New York: Oxford University Press.
35. Tolin D.F., Maltby N., Diefenbach G.J., Hannan S.E., Worhunsky P. Cognitive behavioral therapy for medication nonresponders with obsessive-compulsive disorder: A wait-list controlled open trial. Journal of Clinical Psychiatry 2004, 65:922-931.
36. Tyron W.W. A simplified time-series analysis for evaluating treatment interventions. Journal of Applied Behavior Analysis 1982, 15:423-429.
37. Wang P.S., Berglund P., Kessler R.C. Recent care of common mental disorders in the United States: Prevalence and conformance with evidence-based recommendations. Journal of General Internal Medicine 2000, 15:284-292.
38. Wilhelm S., Buhlmann U., Tolin D.F., Meunier S.A., Pearlson G.D., Reese H.E., Rauch S.L. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. American Journal of Psychiatry 2008, 165:335-341.
39. Woody S.R., Steketee G., Chambless D.L. Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale. Behavior Research and Therapy 1995, 33:597-605.
40. Young L.C. On randomness in ordered sequences. Annals of Mathematical Statistics 1941, 12:153-162.
41. Zanarini M.C., Skodol A.E., Bender D., Dolan R., Sanislow C., Schaefer E., Gunderson J.G. The Collaborative Longitudinal Personality Disorders Study: Reliability of axis I and II diagnoses. Journal of Personality Disorders 2000, 14:291-299.